The level of hemophilia care has significantly improved over the last few decades. Despite all improvements, the development and management of neutralizing antibodies i.e. inhibitors remains a major complication to treatment with factor concentrates.

The aim of this course is to summarize and highlight the current pre-clinical and clinical knowledge in the inhibitor area in an interactive way based on lectures and case discussions.

Target group: Physicians treating hemophilia from all over the world. Participants should be affiliated to a hemophilia centre and have a proven future commitment to this field.

The course is a collaboration between Lund University and Skåne University Hospital (Malmö Centre for Thrombosis and Haemostasis).

LIPUS (Institute for the Professional Development of Physicians in Sweden) will review the course (www.lipus.se).

CME (Continuing Medical Education) application pending.

Good English-speaking skills are required.

Closing date for applications: 18 September 2017.

The course is sponsored by an unrestricted grant from Shire.

CONTACT
For more information please visit: www.med.lu.se/koag (press Utbildning) and/or contact us:

Concerning course content:
Camilla Månsson
Research Administrator
Phone: +46 (0) 40-33 32 02
camilla.mansson@med.lu.se
Dept of Translational Medicine
Lund University

Concerning application:
Ida Burguete Holmgren
Project Coordinator
ida.burguete_holmgren@education.lu.se
Lund University
Commissioned Education